ProMIS Alzheimer Drug: 4.4% ARIA, No Brain Swelling
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ProMIS Neurosciences reported Tuesday interim data from its amyloid-targeting Alzheimer's trial, showing a total ARIA rate of 4.4% in a blinded pooled safety analysis combining drug and placebo arms.
- All ARIA cases were mild and asymptomatic, with zero incidences of ARIA-E, the more severe side effect involving brain swelling.
- Every case was classified as ARIA-H, involving tiny brain bleeds rather than the swelling seen in ARIA-E.
- ProMIS said the results suggest its amyloid-targeting candidate could be safer than currently approved Alzheimer's treatments.
Why it matters: ProMIS reported a 4.4% total ARIA rate — all mild, asymptomatic ARIA-H bleeds with zero ARIA-E cases — in a blinded interim analysis pooling drug and placebo arms, results the company said suggest its amyloid-targeting Alzheimer's candidate could be safer than currently approved treatments.
Ask SkimNews
